Nonalcoholic Fatty Liver Disease Brazilian Society of Hepatology Consensus

Cotrim, Helma Pinchemel; Parise, Edison Roberto; Figueiredo-Mendes, Cláudio; Galizzi-Filho, Joäo; Porta, Gilda; Oliveira, Cláudia Pinto Marques Souza de

doi:10.1590/s0004-28032016000200013

Cited by 37 publications

(53 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 Most studies reporting the prevalence of NAFLD in South America were performed in Brazil. 21 Nevertheless, in a study from Chile, the prevalence of NAFLD (using ultrasound) was estimated to be 23%. 22 A study from Colombia, which also used ultrasound, reported a prevalence rate of 26.6% in males.…”

Section: Prevalence and Incidence Of Nafldmentioning

confidence: 99%

Non-alcoholic fatty liver disease – A global public health perspective

Younossi

2019

Journal of Hepatology

1,446

1,169

View full text Add to dashboard Cite

As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea. NAFLD and NASH carry a large economic burden and create poor health-related quality of life. Despite this important burden, we are only beginning to understand its mechanisms of pathogenesis and the contribution of environmental and genetic factors to the risk of developing a progressive course of disease. Research is underway to identify appropriate non-invasive diagnostic methods and effective treatments. Although the risk of liver-related mortality is increased in patients with NAFLD and liver fibrosis stages F3 or F4, the leading cause of death is cardiovascular disease. Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NAFLD and progressive liver disease.

show abstract

Section: Prevalence and Incidence Of Nafldmentioning

confidence: 99%

Non-alcoholic fatty liver disease – A global public health perspective

Younossi

2019

Journal of Hepatology

1,446

1,169

View full text Add to dashboard Cite

show abstract

“…Studies have found that 11.3% of patients with cirrhosis due to NASH developed HCC within 5 years, while in patients with cirrhosis due to alcohol, the rate is 12.5% over the same time frame [1] . Compared with the benign course of NAFL, NASH patients have an 8-fold increased chance of progressing to advanced fibrosis, in addition to an increased risk of liver-related death and of cardiovascular disease [2,12] . The main risk factors involved in the occurrence of HCC in cirrhotic patients due to NASH are male gender, age over 70 years-old, diabetes and hypertension [13] .…”

Section: Discussionmentioning

confidence: 99%

“…American Association for the Study of the Liver, European Association for the Study of the Liver and the Brazilian Society of Hepatology do not recommend routine HCC screening in non-cirrhotic NASH patients justifying that the large population of NAFL/NASH patients makes systematic surveillance impracticable [4,12,35] .…”

Section: Discussionmentioning

confidence: 99%

Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis

Onzi¹,

Moretti²,

Balbinot³

et al. 2019

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease has become the leading chronic liver disease in the developed world, with a prevalence of 6%-35%. Its pathological spectrum ranges from simple steatosis (non-alcoholic fatty liver) to different degrees of inflammation and liver cell damage [non-alcoholic steatohepatitis (NASH)]. NASH has gained attention in recent years because of its association with hepatocellular carcinoma (HCC). Although the occurrence of HCC is more frequent in the presence of cirrhosis, studies have shown that hepatic carcinogenesis may also develop in the context of NASH without association with advanced fibrosis, as well as from simple steatosis. Evidence of the onset of HCC in the absence of cirrhosis is of concern, since recent surveillance and screening guidelines for liver cancer do not include this population subgroup. Therefore, it is imperative that new effective screening and monitoring measures for HCC, or even the reformulation of these recommendations, be taken to handle these patients considered to be at high risk. The present paper aims to review the literature on the occurrence of HCC in patients with NASH with or without cirrhosis. In addition, we report a case showing the development of HCC in a patients with NASH without cirrhosis.

show abstract

“…Prilikom postavljanja dijagnoze nealkoholne masne jetre neophodno je isključiti značajnu konzumaciju alkohola (sedmični unos alkohola manji od 140 grama za osobe muškog pola, odnosno manji od 120 grama za žene). [5][6][7][8] Metabolički sindrom i hipotiroidizam su nezavisni faktori rizika za kardiovaskularne bolesti.…”

Section: Uvodunclassified

“…Smanjena funkcija štitne žlijezde može predstavljati nezavisni faktor rizika za nastanak hepatične steatoze. [5][6][7][8]…”

Section: Uvodunclassified

Role of hypothyroidism in the onset of metabolic syndrome and hepatic steatosis

Jandrić-Kočić¹

2019

Med gl Spec bol štit Zlatibor

View full text Add to dashboard Cite

Uloga hipotiroidizma U nastankU metaboličkog sindroma i hepatične steatoze Uvod: Kontrolisane studije ukazuju da smanjena funkcija štitne žlijezde može predstavljati nezavisni faktor rizika za nastanak elemenata metaboličkog sindroma i hepatične steatoze, koja se smatra jetrenom komponentom metaboličkog sindroma. Cilj: Istraživanje je imalo za cilj ispitati ulogu hipotiroidizma u nastanku metaboličkog sindroma i hepatične steatoze. Metode: Istraživanje je obuhvatilo 27 (54.0%) žena i 23 (46.0%) muškarca prosječne starosti 48 ± 6.9 godina sa verifikovanim hipotiroidizmom i 29 (58.0%) žena i 21(42.0%) muškarca prosječne starosti 45 ± 5.8 godina sa urednom funkcijom štitne žlijezde. Podaci su prikupljeni na osnovu anamneze, fizikalnog pregleda, dostupne medicinske dokumentacije, laboratorijskih analiza i ultrazvučnog pregleda. Rezultati: Hipotiroidizam (otvoreni i subklinički) ima statistički značajnu ulogu u nastanku metaboličkog sindroma i hepatične steatoze (p<0.05). Zaključak: Pravovremena dijagnoza i adekvatan terapijski menadžment poremećaja štitne žlijezde značajno bi smanjili incidencu kardiovaskularnih komplikacija, mogućnost nastanka steatohepatitisa, troškove zdravstvene zaštite i gubitak prihoda zbog izgubljene produktivnosti. Ključne riječi: hipotiroidizam, metabolički, sindrom, hepatična steatoza. Role of hypothyroidism in the onset of metabolic syndrome and hepatic steatosis Introduction: The comorbidity of metabolic syndrome and hypothyroidism results in significant progression of the atherosclerotic process, bearing in mind the overlap of pathogenic mechanisms. Reduced thyroid function is an independent risk factor for liver steatosis, which is considered a hepatic component of metsbolic syndrome. Objective: The study aimed to examine the role of hypothyroidism in the onset of metabolic syndrome and hepatic steatosis.

show abstract

Nonalcoholic Fatty Liver Disease Brazilian Society of Hepatology Consensus

Cited by 37 publications

References 9 publications

Non-alcoholic fatty liver disease – A global public health perspective

Non-alcoholic fatty liver disease – A global public health perspective

Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis

Role of hypothyroidism in the onset of metabolic syndrome and hepatic steatosis

Contact Info

Product

Resources

About